Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group-Reference-Cited by-同舟云学术

Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group

Published:2018-07-09 Issue:6 Volume:182 Page:859-869
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Cairo Mitchell¹^ORCID,Auperin Anne²,Perkins Sherrie L.³,Pinkerton Ross⁴,Harrison Lauren¹,Goldman Stanton⁵,Patte Catherine²

Affiliation:

1. Maria Fareri Children's Hospital; New York Medical College; Valhalla NY USA

2. Gustave Roussy; Villejuif France

3. University of Utah Health Sciences Center; Salt Lake City UT USA

4. University of Queensland; Saint Lucia Qld Australia

5. Medical City Children's Hospital; Dallas TX USA

Funder

National Cancer Institute

Cancer Research Campaign United Kingdom Children's Cancer Study Group

Institut Gustave-Roussy

Pediatric Cancer Research Foundation

St. Baldrick's Foundation

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15491/fullpdf

Reference50 articles.

1. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia;Anoop;Leukaemia & Lymphoma,2012

2. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol;Atra;British Journal of Cancer,2000

3. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL;Awasthi;British Journal of Haematology,2015

4. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report;Barth;British Journal of Haematology,2013

5. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study;Bowman;Journal of Clinical Oncology,1996

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant;BMC Cancer;2023-12-20

2. Optimal dosage of rituximab for children with Burkitt lymphoma;Annals of Hematology;2023-12-13

3. CD19 CAR-T cell therapy for Relapsed or Refractory Diffuse Large B Cell Lymphoma; Why does it Fail?;Seminars in Hematology;2023-12

4. Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy;Cancer Cell International;2023-11-19

5. Real-World Outcomes of Adolescents and Young Adults with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Cohort Study;Journal of Adolescent and Young Adult Oncology;2023-10-16